Novartis Kymriah® receives FDA Regenerative Medicine Advanced Therapy designation in follicular lymphoma

NEXT STORY
Saniona Reports Positive Topline Results from Phase 2 Trial of Tesomet in Hypothalamic Obesity
PREV STORY
First quarter with 2% growth in Swiss francs, 7%[1] at constant exchange rates
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Telix Pharmaceuticals and Osaka University receive Japan Science and Technology Agency Funding for Alpha Nuclide Research

KYOTO and OSAKA, Japan, May 30, 2018 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX:TLX) ...

author_avatar
NASDAQ Market News

Helsinn Group and Angelini support Satellite Symposium at MASCC/ISOO 2018 Annual Meeting

Helsinn Group and Angelini support Satellite Symposium at MASCC/ISOO 2018 Annual Meeting Leading cancer ...

author_avatar
NASDAQ Market News

Major Cancer Journal Highlights Data From An Inovio-Sponsored Trial In Which A Patient Achieved Full Remission After Dosing With DNA Immunotherapy and Checkpoint Inhibitor

Study results published in Clinical Cancer Research shows that DNA immunotherapy approach drove T ...

author_avatar
NASDAQ Market News